https://pubmed.ncbi.nlm.nih.gov/39934679/ cholestatic liver disease

BMC Gastroenterol. 2025 Feb 11;25(1):75.
doi: 10.1186/s12876-025-03661-0.

Impact of steatotic liver disease subtypes, sarcopenia, and fibrosis on all-cause and cause-specific mortality: a 15.7-year cohort study

Yebei Liang # 1 2 3 4, Xiaoqi Ye # 5, Min Pan 1 2 3 4, Yijun Chen 1 2 3 4, Yeqing Yuan 6, Li Luo 7 8 9 10

Abstract

Background: Steatotic liver disease (SLD) was a newly proposed disease category derived from metabolic dysfunction-associated fatty liver disease (MAFLD). MAFLD and sarcopenia were independent risk factors for mortality. We aimed to evaluate the impacts of SLD subtypes, MAFLD, and sarcopenia on mortality.

https://pubmed.ncbi.nlm.nih.gov/39618087/ Autoimmune liver disease

J Pediatr Gastroenterol Nutr. 2024 Dec 1.
doi: 10.1002/jpn3.12424. Online ahead of print.

Current practice in the management of paediatric autoimmune liver disease in Europe

Mara Cananzi 1, Marianne Hørby Jørgensen 2, Gustav Buescher 3, Ruth De Bruyne 4, Marianne Samyn 5; ESPGHAN Hepatology Interest Group and of the ERN RARE‐LIVER Autoimmune Hepatitis Working Group
Affiliations expand
PMID: 39618087

DOI: 10.1002/jpn3.12424
Abstract

https://pubmed.ncbi.nlm.nih.gov/39704261/ Primary sclerosing cholangitis

J Pediatr Gastroenterol Nutr. 2024 Dec 20.
doi: 10.1002/jpn3.12443. Online ahead of print.

Determining the time to cholangiocarcinoma in pediatric-onset PSC-IBD

Batul Kaj-Carbaidwala 1, Johan Fevery 2, Douglas G Adler 3, Annika Bergquist 4, Lissy de Ridder 5, Mark Deneau 6, Corinne Gower-Rousseau 7, Roger W Chapman 8, Kate D Lynch 8 9, Catherine A M Stedman 10, David C Wilson 11, Uzma Shah 1, Lipika Goyal 12, Harland S Winter 1, Jochen K Lennerz 13
Affiliations expand
PMID: 39704261

DOI: 10.1002/jpn3.12443
Abstract